ArticleScientific reports2026
Antibacterial and antivirulence activity of biosynthesized silver nanoparticles by Pseudomonas lurida against several plant pathogenic bacteria.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanohydroxyapatite composites' toxicity and biosafety for safe clinical translation.Nanoscale advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the synthesis of metal nanoparticles using bacteria has been extensively studied and recognized as a non-toxic and efficient method applicable in the control of bacterial pathogens. This study aims to investigate the potential of endophytic bacteria in synthesizing silver nanoparticles (AgNPs), characterize the produced silver nanoparticles, and their antibacterial activity. Pseudomonas lurida Bi6 was able to biosynthesize AgNPs. Scanning electron microscopy (SEM) showed that biosynthesized AgNPs exhibited a spherical shape with an average size of 37 nm. Additionally, the biosynthesized silver nanoparticles were evaluated for their antibacterial activity against various bacterial pathogens. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of AgNPs against Pseudomonas tolaasii, Ralstonia solanacearum, and Agrobacterium tumefaciens were 25, 50, and 50μg/ml, respectively. The biosynthesized AgNPs showed an MBC value of 50, 100, and 100 µg/ml against P. tolaasii, R. solanacearum, and A. tumefaciens, respectively. At sub-MIC concentrations, AgNPs showed various negative effects on virulence traits of all three pathogens, such as motility behaviors, chemotaxis, exopolysaccharide production, and biofilm formation that is important for pathogenicity. The SEM micrographs revealed that biosynthesized AgNPs enhance various morphological abnormalities in the treated cells. Our study indicates that biosynthesized AgNPs exhibit strong antibacterial activity against bacterial pathogens studied. Information on the mechanisms mediated by AgNPs as an eco-friendly and safe tool against bacterial pathogens is important to the design of new and more efficient disease control strategies. However, field experiments need to be performed under controlled conditions to scale up the current work and find out the efficacy of AgNPs on a larger scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.